$1.39
+0.04 (+2.96%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BMEA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional
Held by 8 tracked-famous managers (MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, +3 more) · FINRA short interest 22.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: icovamenib 100 mg, Placebo | Type 2 Diabetes | 60 | Jun 2027 | ≤ 314 d | 2026-06-15 |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic controlRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: icovamenib 100mg, Placebo | Type 2 Diabetes | 60 | Mar 2027 | ≤ 223 d | 2026-08-07 |
| Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT07223216Assess safety and tolerability of BMF-650Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: BMF-650 | Obesity | 80 | May 2026 | — | 2026-04-09 |
| A Phase 1 Study of BMF-500 in Adults With Acute LeukemiaNCT05918692Evaluate the safety and tolerability of BMF-500 by incidence of Treatment Emergent Adverse Events (TEAEs).Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: BMF-500 | Acute Myeloid Leukemia | 35 | Apr 2026 | — | 2026-02-23 |
| Food Effect Study in Healthy VolunteersNCT07254286Evaluate food effect and PK profile of icovamenib capsule formulation in fed and fasted statesRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Icovamenib, Icovamenib HPMC | Healthy Volunteer | 60 | 2026-01-14actual | — | 2026-02-11 |
| Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes MellitusNCT06152042To assess the effect on endogenous insulin secretionRandomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor made a business decision to terminate the study based on prioritization of portfolio. | Drug: BMF-219 | Type 1 Diabetes Mellitus | 37 | 2025-05-20actual | — | 2026-05-14 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2025-02-13actual | — | 2025-07-03 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal CancerNCT05631574To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors | 13 | 2025-01-15actual | — | 2025-02-07 |
| Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)NCT05731544Safety AssessmentsRandomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: BMF-219 | Type 2 Diabetes Mellitus | 443 | 2024-11-18actual | — | 2025-11-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19